Show More Sheng Zhang, Fei Liang, and Xichun Hu, Shanghai Cancer Center and Shanghai Medical College, Fudan University, Shanghai; and Wenfeng Li, Affiliated Hospital of Qingdao University, Qingdao, ...
Claims of differential treatment effects were largely rated as “low credibility” or “very low credibility.” Subgroup analyses in cancer trials may not be credible, and their results should be ...
Efforts to improve reporting clinical trial results have led to the development of guidelines such as those recommended by the CONSORT group. 3,4 Transparent and comprehensive reporting of subgroup ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results